ClinicalTrials.gg
WithdrawnNCT04452097Updated Dec 29, 2025

Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS

A Phase 1/2 interventional study of Human umbilical cord mesenchymal stem cells + best supportive care and Placebo control + best supportive care in COVID-19, ARDS and Acute Respiratory Distress Syndrome, sponsored by Baylx Inc.. Withdrawn. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Baylx Inc. · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
It is a strategic decision by the company, coupled with low incidence of ARDS cases following widespread vaccination efforts.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a phase 1/2a study including 2 parts, phase 1 and phase 2a. The phase 1 part is an open-label, single-arm, dose-escalating study to evaluate the safety and explore the dose limiting toxicity and maximum tolerated dose of a human umbilical cord derived mesenchymal stem cell product (BX-U001) in severe COVID-19 pneumonia patients with acute respiratory distress syndrome (ARDS). Qualified subjects after the screening will be divided into low, medium, or high dose groups to receive a single intravenous infusion of BX-U001 at the dose of 0.5×10\^6, 1.0×10\^6, or 1.5×10\^6 cells/kg of body weight, respectively. The Phase 2a part is a randomized, placebo-controlled, double-blind clinical trial examining the safety and biological effects of BX-U001 at the appropriate dose selected from phase 1 for severe COVID-19 pneumonia patients with the same inclusion/exclusion criteria as the phase 1 part.

02

Conditions studied

  • COVID-19
  • ARDS
  • Acute Respiratory Distress Syndrome
03

In context

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

Baylx Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged between 18 and 80;
  2. Laboratory (RT-PCR, Gene Sequencing or Antibody) confirmed cases of severe COVID-19 pneumonia with mild to moderate ARDS (Berlin definition);
  3. Patients are intubated;
  4. Patients who voluntarily adhere to the research procedures and ensure good compliance during the research period;
  5. Patients who fully understand the research nature of this study and sign written .

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have received drug (except for Remdesivir) for the treatment of COVID-19 within 30 days before screening;
  2. Subjects who are pregnant, breastfeeding or whose urinary pregnancy test is positive before participation in the study; subjects who are pregnant, breastfeeding, have a birth plan, or are unwillingness to use during the study period and within 12 months of infusion; except for subjects who have sterilization surgery or menopause during the study period;
  3. Within 3 days before screening/randomization, subjects who have used high-dose that is equivalent to methylprednisolone >240 mg/day or irregular use of systemic corticosteroids to treat other diseases that could affect the efficacy evaluated by the investigator;
  4. Subjects receiving extracorporeal membrane oxygenation (ECMO) support.
  5. Subjects who are allergic to low-molecular-weight heparin calcium or human albumin;
  6. Subjects with ongoing malignant tumors.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Phase 1 Low-dose Group

    Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 0.5 million cells/kg in addition to standard of care treatment.

    Biological: Human umbilical cord mesenchymal stem cells + best supportive care

  • Experimental
    Phase 1 Middle-dose Group

    Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1 million cells/kg in addition to standard of care treatment.

    Biological: Human umbilical cord mesenchymal stem cells + best supportive care

  • Experimental
    Phase 1 High-dose Group

    Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1.5 million cells/kg in addition to standard of care treatment.

    Biological: Human umbilical cord mesenchymal stem cells + best supportive care

  • Experimental
    Phase 2a Treatment Group

    Eligible subjects will receive a single infusion of hUC-MCS product at the selected dose from phase 1 in addition to standard of care treatment.

    Biological: Human umbilical cord mesenchymal stem cells + best supportive care

  • Placebo comparator
    Phase 2a Control Group

    Eligible subjects will receive a single infusion of placebo control and standard of care treatment.

    Other: Placebo control + best supportive care

Interventions

  • BiologicalHuman umbilical cord mesenchymal stem cells + best supportive care

    hUC-MSC product will be administered intravenously in addition to the standard of care treatment.

  • OtherPlacebo control + best supportive care

    Placebo control will be administered intravenously in addition to the standard of care treatment.

06

What researchers measure

Primary outcomes

  1. Incidence of infusion-related adverse events

    Safety will be defined by the incidence of infusion-related adverse events as assessed by the treating physician

    Time frame: Day 3

  2. Incidence of any treatment-emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)

    Safety will be defined by the incidence of TEAEs and TESAEs as assessed by the treating physician

    Time frame: Day 28

Secondary outcomes

  1. Selection of an appropriate dose of BX-U001 for the following Phase 2 study

    The dose will be selected based on the assessment of dose-limiting toxicity and maximum tolerated dose.

    Time frame: Day 28

  2. All-cause mortality

    Time frame: Day 28

  3. Proportion of patients achieving clinical response by the improvement of at least 2 points on the 7-point ordinal scale.

    The scale is as follows: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices 4. Hospitalized, requiring low flow supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care 7. Not hospitalized.

    Time frame: Day 14

  4. Duration of ICU stay

    Time frame: Day 28

  5. Duration of hospital stay

    Time frame: Day 28

  6. Changes in blood cytokine levels

    Time frame: Day 28

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jul 2027, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2020
First posted
Jun 30, 2020
StartEst.
Jun 1, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Sep 28, 2027
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04452097
Lead sponsor
Baylx Inc.
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Jun 1, 2026 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Sep 28, 2027 (estimated)
Last update
Dec 29, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion